Scimago Lab
powered by Scopus
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 2329-0358

Get your full text copy in PDF

Induction therapy, tacrolimus plasma concentration, and duration of intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation

Tomasz Urbanowicz, Ewa Straburzyńska-Migaj, Aneta Klotzka, Hanna Baszyńska-Wachowiak, Marcin Misterski, Stefan Grajek, Marek Jemielity

(Department of Cardiac Surgery and Transplantology, Chair of Cardio-Thoracic Surgery, Poznań University of Medical Sciences, Poznań, Poland)

Ann Transplant 2014; 19:494-498

DOI: 10.12659/AOT.890816

Background: Although survival among heart recipients has increased, a limiting factor is chronic adverse effects of immunosuppression therapy.
Material and Methods: We performed a retrospective analysis of 22 patients (19 men and 3 women) with a mean age of 48±12 years who underwent orthotropic heart transplantation. There were 20 (91%) patients who received induction therapy (basiliximab, Simulect, Novartis Europharm Limited). All patients were treated with standard triple immunosuppressive regimen (tacrolimus, mycophenolate mofetil, and steroids).
Results: Patients were divided into 2 groups according to postoperative peripheral cytopenia diagnosis. There were 16 (73%) in the cytopenic group and 6 (27%) in the non-cytopenic group. Mean time of peripheral leucopenia detection was 65±13 days following surgery. The blood leucocyte count was 0.98±0.2×10^3/mm3 vs. 5.85±0.9×10^3/mm3 in patients with peripheral cytopenia compared to non-cytopenic patients (p<0.01). There was a statistically important difference in duration of intensive care unit stay between the 2 groups (p<0.01). A correlation between tacrolimus serum concentration and risk for leucopenia was also detected (p<0.05).
Conclusions: Basiliximab administration as induction therapy, tacrolimus serum concentration, and duration of intensive care unit stay are risk factors for leucopenia.

Keywords: Antibodies, Monoclonal, Heart Transplantation, Intensive Care, Tacrolimus

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree